Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study

Sabine Kayser; Richard F. Schlenk; Delphine Lebon; Martin Carre; Katharina S. Götze; Friedrich Stölzel; Ana Berceanu; Kerstin Schäfer-Eckart; Pierre Peterlin; Yosr Hicheri; Ramy Rahmé; Emmanuel Raffoux; Fatiha Chermat; Stefan W. Krause; Walter E. Aulitzky; Sophie Rigaudeau; Richard Noppeney; Celine Berthon; Martin Görner; Edgar Jost; Philippe Carassou; Ulrich Keller; Corentin Orvain; Thorsten Braun; Colombe Saillard; Ali Arar; Volker Kunzmann; Mathieu Wemeau; Maike de Wit; Dirk Niemann; Caroline Bonmati; Carsten Schwänen; Julie Abraham; Ahmad Aljijakli; Stéphanie Haiat; Alwin Krämer; Albrecht Reichle; Martina Gnadler; Christophe Willekens; Karsten Spiekermann; Wolfgang Hiddemann; Carsten Müller-Tidow; Christian Thiede; Christoph Röllig; Hubert Serve; Martin Bornhäuser; Claudia D. Baldus; Eva Lengfelder; Pierre Fenaux; Uwe Platzbecker; Lionel Adès

doi:10.3324/haematol.2021.278722

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study

Sabine Kayser, Richard F. Schlenk, Delphine Lebon, Martin Carre, Katharina S. Götze, Friedrich Stölzel, Ana Berceanu, Kerstin Schäfer-Eckart, Pierre Peterlin, Yosr Hicheri, Ramy Rahmé, Emmanuel Raffoux, Fatiha Chermat, Stefan W. Krause, Walter E. Aulitzky, Sophie Rigaudeau, Richard Noppeney, Celine Berthon, Martin Görner, Edgar JostPhilippe Carassou, Ulrich Keller, Corentin Orvain, Thorsten Braun, Colombe Saillard, Ali Arar, Volker Kunzmann, Mathieu Wemeau, Maike de Wit, Dirk Niemann, Caroline Bonmati, Carsten Schwänen, Julie Abraham, Ahmad Aljijakli, Stéphanie Haiat, Alwin Krämer, Albrecht Reichle, Martina Gnadler, Christophe Willekens, Karsten Spiekermann, Wolfgang Hiddemann, Carsten Müller-Tidow, Christian Thiede, Christoph Röllig, Hubert Serve, Martin Bornhäuser, Claudia D. Baldus, Eva Lengfelder, Pierre Fenaux, Uwe Platzbecker, Lionel Adès

Default

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.

Original language	English
Pages (from-to)	3100-3106
Number of pages	7
Journal	Haematologica
Volume	106
Issue number	12
DOIs	https://doi.org/10.3324/haematol.2021.278722
State	Published - Dec 2021

Access to Document

10.3324/haematol.2021.278722

Cite this

Kayser, S., Schlenk, R. F., Lebon, D., Carre, M., Götze, K. S., Stölzel, F., Berceanu, A., Schäfer-Eckart, K., Peterlin, P., Hicheri, Y., Rahmé, R., Raffoux, E., Chermat, F., Krause, S. W., Aulitzky, W. E., Rigaudeau, S., Noppeney, R., Berthon, C., Görner, M., ... Adès, L. (2021). Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study. Haematologica, 106(12), 3100-3106. https://doi.org/10.3324/haematol.2021.278722

@article{942eb237bbb24bad9894f341ff3591b3,

title = "Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study",

abstract = "The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.",

author = "Sabine Kayser and Schlenk, {Richard F.} and Delphine Lebon and Martin Carre and G{\"o}tze, {Katharina S.} and Friedrich St{\"o}lzel and Ana Berceanu and Kerstin Sch{\"a}fer-Eckart and Pierre Peterlin and Yosr Hicheri and Ramy Rahm{\'e} and Emmanuel Raffoux and Fatiha Chermat and Krause, {Stefan W.} and Aulitzky, {Walter E.} and Sophie Rigaudeau and Richard Noppeney and Celine Berthon and Martin G{\"o}rner and Edgar Jost and Philippe Carassou and Ulrich Keller and Corentin Orvain and Thorsten Braun and Colombe Saillard and Ali Arar and Volker Kunzmann and Mathieu Wemeau and {de Wit}, Maike and Dirk Niemann and Caroline Bonmati and Carsten Schw{\"a}nen and Julie Abraham and Ahmad Aljijakli and St{\'e}phanie Haiat and Alwin Kr{\"a}mer and Albrecht Reichle and Martina Gnadler and Christophe Willekens and Karsten Spiekermann and Wolfgang Hiddemann and Carsten M{\"u}ller-Tidow and Christian Thiede and Christoph R{\"o}llig and Hubert Serve and Martin Bornh{\"a}user and Baldus, {Claudia D.} and Eva Lengfelder and Pierre Fenaux and Uwe Platzbecker and Lionel Ad{\`e}s",

note = "Publisher Copyright: {\textcopyright} 2021 Ferrata Storti Foundation",

year = "2021",

month = dec,

doi = "10.3324/haematol.2021.278722",

language = "English",

volume = "106",

pages = "3100--3106",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "12",

}

Kayser, S, Schlenk, RF, Lebon, D, Carre, M, Götze, KS, Stölzel, F, Berceanu, A, Schäfer-Eckart, K, Peterlin, P, Hicheri, Y, Rahmé, R, Raffoux, E, Chermat, F, Krause, SW, Aulitzky, WE, Rigaudeau, S, Noppeney, R, Berthon, C, Görner, M, Jost, E, Carassou, P, Keller, U, Orvain, C, Braun, T, Saillard, C, Arar, A, Kunzmann, V, Wemeau, M, de Wit, M, Niemann, D, Bonmati, C, Schwänen, C, Abraham, J, Aljijakli, A, Haiat, S, Krämer, A, Reichle, A, Gnadler, M, Willekens, C, Spiekermann, K, Hiddemann, W, Müller-Tidow, C, Thiede, C, Röllig, C, Serve, H, Bornhäuser, M, Baldus, CD, Lengfelder, E, Fenaux, P, Platzbecker, U & Adès, L 2021, 'Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study', Haematologica, vol. 106, no. 12, pp. 3100-3106. https://doi.org/10.3324/haematol.2021.278722

TY - JOUR

T1 - Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide

T2 - An international collaborative study

AU - Kayser, Sabine

AU - Schlenk, Richard F.

AU - Lebon, Delphine

AU - Carre, Martin

AU - Götze, Katharina S.

AU - Stölzel, Friedrich

AU - Berceanu, Ana

AU - Schäfer-Eckart, Kerstin

AU - Peterlin, Pierre

AU - Hicheri, Yosr

AU - Rahmé, Ramy

AU - Raffoux, Emmanuel

AU - Chermat, Fatiha

AU - Krause, Stefan W.

AU - Aulitzky, Walter E.

AU - Rigaudeau, Sophie

AU - Noppeney, Richard

AU - Berthon, Celine

AU - Görner, Martin

AU - Jost, Edgar

AU - Carassou, Philippe

AU - Keller, Ulrich

AU - Orvain, Corentin

AU - Braun, Thorsten

AU - Saillard, Colombe

AU - Arar, Ali

AU - Kunzmann, Volker

AU - Wemeau, Mathieu

AU - de Wit, Maike

AU - Niemann, Dirk

AU - Bonmati, Caroline

AU - Schwänen, Carsten

AU - Abraham, Julie

AU - Aljijakli, Ahmad

AU - Haiat, Stéphanie

AU - Krämer, Alwin

AU - Reichle, Albrecht

AU - Gnadler, Martina

AU - Willekens, Christophe

AU - Spiekermann, Karsten

AU - Hiddemann, Wolfgang

AU - Müller-Tidow, Carsten

AU - Thiede, Christian

AU - Röllig, Christoph

AU - Serve, Hubert

AU - Bornhäuser, Martin

AU - Baldus, Claudia D.

AU - Lengfelder, Eva

AU - Fenaux, Pierre

AU - Platzbecker, Uwe

AU - Adès, Lionel

PY - 2021/12

Y1 - 2021/12

N2 - The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.

AB - The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.

UR - http://www.scopus.com/inward/record.url?scp=85121037273&partnerID=8YFLogxK

U2 - 10.3324/haematol.2021.278722

DO - 10.3324/haematol.2021.278722

M3 - Article

C2 - 34047178

AN - SCOPUS:85121037273

SN - 0390-6078

VL - 106

SP - 3100

EP - 3106

JO - Haematologica

JF - Haematologica

IS - 12

ER -

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: An international collaborative study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this